Cytokinetics Inc（CYTK）の財務CYTKCytokinetics Inc

Evaluating the bottom line, Cytokinetics, Incorporated maintains a gross margin of 80.46%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -625.95%, while the net margin is -694.39%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively CYTK converts its operational activities into shareholder value.

In the context of the broader market, CYTK competes directly with industry leaders such as SYRE and IBRX. With a market capitalization of $8.82B, it holds a leading position in the sector. When comparing efficiency, CYTK's gross margin of 80.46% stands against SYRE's N/A and IBRX's 99.42%. Such benchmarking helps identify whether Cytokinetics, Incorporated is trading at a premium or discount relative to its financial performance.

Cytokinetics has shown fluctuating revenue, with Q2 2026 revenue at 28,624,000 USD, but it continues to report significant net losses, with a net income of -198,762,000 USD for the same quarter. The gross margin has decreased to 80.46%, down from 100% in previous quarters, indicating potential cost pressures.